Received Feb 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
a patient received Twinrix -1st dose in May 2024 and 2nd dose October 2024; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 57-year-old female patient who received HAB (Twinrix) for prophylaxis. Previously administered products included Twinrix (1st dose received in May 2024). In OCT-2024, the patient received the 2nd dose of Twinrix. In OCT-2024, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: a patient received Twinrix -1st dose in May 2024 and 2nd dose October 2024). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 11-FEB-2025 The reporter reported a patient received Twinrix 1st dose in May 2024 and 2nd dose October 2024. The reporter declined to provide patient demographics, Lot and Expiration dates of vaccines were not available at time of call. The reporter consented to follow up. The patient received 2nd dose of Shingrix, later than the recommended interval, which led to lengthening of vaccination schedule.